<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95012</article-id><article-id pub-id-type="doi">10.26442/2075-1753_2018.1.62-65</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Cerebroprotection in patients with hypertension and comorbid disease</article-title><trans-title-group xml:lang="ru"><trans-title>Церебропротекция в лечении пациентов с артериальной гипертонией и коморбидными состояниями</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mamedov</surname><given-names>M. N</given-names></name><name xml:lang="ru"><surname>Мамедов</surname><given-names>Мехман Ниязи оглы</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф., рук. лаб. по разработке междисциплинарного подхода в профилактике хронических неинфекционных заболеваний отд. профилактики коморбидных состояний</p></bio><email>mmamedov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ НМИЦ ПМ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2018</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en">VOL 20, NO1 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 20, №1 (2018)</issue-title><fpage>62</fpage><lpage>65</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95012">https://consilium.orscience.ru/2075-1753/article/view/95012</self-uri><abstract xml:lang="en"><p>The review concerns some aspects of cerebrovascular comorbidities and major vessels disease. Hypertension is one of the main reasons for cerebral stroke. For primary and secondary prevention of cerebral stroke and its late effects development, adequate treatment of hypertension is required. Cognitive impairment in elderly patients is widely discussed nowadays. Effective antihypertensive therapy with calcium antagonists, such as nitrendipine, reduces cognitive impairment and demention development, particularly, of vascular genesis.</p></abstract><trans-abstract xml:lang="ru"><p>В обзорной статье рассматриваются вопросы коморбидности цереброваскулярных заболеваний и поражения других магистральных сосудов. Артериальная гипертония является главной причиной развития мозгового инсульта. С целью первичной и вторичной профилактики мозгового инсульта и его последствий необходима адекватная коррекция артериальной гипертонии. В последнее время активно обсуждаются когнитивные нарушения у пожилых пациентов. Эффективная антигипертензивная терапия с применением антагонистов кальция, к примеру нитрендипина, снижает вероятность развития конгитивных нарушений и деменции, в частности сосудистого генеза.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cerebrovascular disease</kwd><kwd>demention</kwd><kwd>antihypertensive therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>цереброваскулярные заболевания</kwd><kwd>деменция</kwd><kwd>антигипертензивная терапия</kwd><kwd>цереброваскулярные заболевания</kwd><kwd>деменция</kwd><kwd>антигипертензивная терапия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Writing Group Members, Mozaffarian D, Benjamin E.J, Go A.S. et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016; 133 (4): e38-360.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Метельская В.А., Гаврилова Н.Е., Яровая Е.А., Бойцов С.А. Интегрированный биомаркер: возможности неинвазивной диагностики коронарного атеросклероза. Рос. кардиологич. журн. 2017; 6: 132-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Румянцева С.А., Оганов Р.Г., Силина Е.В. Современные концепции лечения пациентов с сосудистой коморбидностью. Кардиоваскулярная терапия и профилактика. 2012; 11 (6): 50-5</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Liakos C.I, Grassos C.A, Babalis D.K; European Society of Hypertension; European Society of Cardiology. 2013 ESH/ESC guidelines for the management of arterial hypertension: what has changed in daily clinical practice? High Blood Press Cardiovasc Prev 2015; 22 (1): 43-53.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ninomiya T, Ohara T, Hirakawa Y et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 2011; 58 (1): 22-8.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Forette F, Seux M.L, Staessen J.A et al; Systolic Hypertension in Europe Investigators. Arch Intern Med 2002; 162 (18): 2046-52.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wang J.G, Staessen J.A, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000; 160: 211-20.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Bachmeier C et al. Selective dihydropyridin compounds facilitate the clearence of amiloid across the blood-brain barrier. Eur J Pharmacology 2011; 659: 124-9.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Peters J, Booth A, Peters R. Potential for specific dihydropyridine calcium channel blockers to have a positive impact on cognitive function in humans: a systematic review. Ther Adv Chronic Dis 2015; 6 (4): 160-9.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents. Curr Med Res Opin 2013; 29 (9): 1045-54.</mixed-citation></ref></ref-list></back></article>
